Human leukocyte antigens (HLA) play an important role in the way the immune system works. HLA proteins are inherited from one’s parents and make up one’s individual HLA type, or immune profile. One of the important functions of the HLA proteins is that they present antigens to T‑Cells. Each T cell has a specific receptor (TCR) that can recognize a particular antigen in the context of an HLA protein. The HLA protein through which a T cell recognizes its target antigen and attacks diseased or cancer cells is known as HLA restriction.
Atara’s off-the-shelf T-cell immunotherapies is composed of a library of T‑Cells with well-characterized HLA restrictions across a wide range of HLA types to cover the majority of the population through a library of off-the-shelf allogeneic T cell immunotherapy candidates:
T‑Cells selectively identify antigen-expressing cells in the context of the restricting HLA allele and become activated
The activated T‑Cells can recognize, expand, and attack the diseased or cancer cells. Once T‑Cells no longer encounter the target antigen, their number will recede.
Developing Investigational T-cell Immunotherapies Based on Clinical Research
A collection of publications and presentations cover various areas of interest.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.